§ 529.1044 Gentamicin sulfate in certain other dosage forms.

(a) Gentamicin sulfate in certain other dosage forms.

§ 529.1044a Gentamicin sulfate in certain other dosage forms.

(a) Specifications. Each milliliter of solution contains 50 or 100 milligrams gentamicin sulfate.

(b) Sponsors. See Nos. 000010, 000061, 000856, 057561, 058005, 059130, and 061623 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is recommended as an aid in the reduction or elimination of the following microorganisms from turkey-hatching eggs: Arizona hinshawii (paracolon), Salmonella st. paul, and Mycoplasma meleagridis.

(2) The drug is added to clean water to provide a dip solution with a gentamicin concentration of 250 to 1,000 parts per million. A concentration of 500 parts per million is recommended. Clean eggs should be held submerged in the gentamicin solution under a vacuum of about 27.5 to 38 centimeters of mercury for 5 minutes followed by additional soaking in gentamicin solution for approximately 10 minutes at atmospheric pressure. Eggs can also be treated by warming them for 3 to 6 hours at approximately 100 °F, then immediately submerging them in gentamicin solution maintained at about 40 °F., keeping the eggs submerged for 10 to 15 minutes.

(3) For use in the dipping treatment of turkey-hatching eggs only. Eggs which have been dipped in the drug shall not be used for food.

§ 529.1115 Halothane.

(a) Specifications. The drug is a colorless, odorless, nonflammable, nonexplosive, heavy liquid containing 0.01 percent thymol as a preservative.

(b) Sponsors. See 000856 and 012164 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Two to 5 percent of inhaled atmosphere for induction of anesthesia; 0.5 to 2 percent for maintenance of anesthesia; 1

(2) Indications for use. For nonfood animals for the induction and maintenance of anesthesia; 1

(3) Limitations. Administered by inhalation. May be administered with either oxygen or a mixture of oxygen and

---

1These conditions have been reviewed by FDA and found effective. NADA’s for similar products for these conditions of use need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency and safety information.